Department of Surgery, Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Surgery, Changning County People's Hospital, Baoshan, Yunnan, China.
J Int Med Res. 2021 Mar;49(3):300060521989200. doi: 10.1177/0300060521989200.
To investigate whether protein regulator of cytokinesis 1 (), which is involved in the regulation of human carcinogenesis, contributes to poor prognosis in patients with cholangiocarcinoma (CCA).
Data and tissues from patients with CCA were retrospectively studied. Immunohistochemical staining and western blotting were used to evaluate and contrast the expression profile at the protein level in CCA tumour and pericarcinomatous tissues from the same study population. Relationships between clinical characteristics and patient survival were observed using univariate and multivariate analyses. Correlations between expression and clinical characteristics were analysed by logistic regression.
A total of 45 patients were included. expression was found to be upregulated in CCA cancer tissues versus pericarcinomatous tissues. Overexpression of was shown to be related to tumour differentiation, tumour node metastasis staging and lymph node metastasis, and was also revealed to be an independent marker of poor CCA prognosis.
The present results suggest that PRC1 may be a prognostic and therapeutic biomarker for patients with CCA.
研究细胞因子调节蛋白 1()是否参与人类致癌作用，进而对胆管癌（CCA）患者的预后产生不良影响。
回顾性研究了 CCA 患者的数据和组织。免疫组织化学染色和 Western blot 用于评估和对比同一研究人群中 CCA 肿瘤组织和癌旁组织中蛋白水平的表达谱。采用单因素和多因素分析观察临床特征与患者生存之间的关系。采用逻辑回归分析 表达与临床特征之间的相关性。
共纳入 45 例患者。发现 CCA 癌组织中 的表达上调。过表达与肿瘤分化、肿瘤淋巴结转移分期和淋巴结转移有关，也是 CCA 预后不良的独立标志物。
本研究结果表明，PRC1 可能是 CCA 患者的预后和治疗生物标志物。
